Clinical Trials
Pioglitazone has been evaluated across numerous clinical trials ranging from Phase 1 to Phase 4, primarily investigating metabolic disorders such as type 2 diabetes mellitus and non-alcoholic fatty liver disease, alongside rare indications including ANCA-associated vasculitis, autoimmune pulmonary alveolar proteinosis, and prostate cancer. Sponsored by academic institutions, pharmaceutical corporations, and government entities like the National Institute of Diabetes and Digestive and Kidney Diseases, these trials span completed, recruiting, and pending recruitment statuses. Additional Phase 2 and Phase 4 investigations evaluate therapeutic regimens for nonalcoholic steatohepatitis and hepatic mitochondrial flux modulation.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05838287 | RECRUITING | Type 2 Diabetes Mellitus in Obese; Heart Failure With Preserved Ejection Fraction |
The University of Texas Health Science Center at San Antonio |
2023-07-10 | PHASE4 |
| NCT07635953 | NOT_YET_RECRUITING | Diabetes Mellitus |
Sun Yat-sen University |
2026-07-01 | PHASE3 |
| NCT06246799 | RECRUITING | Type 2 Diabetes (Adult Onset) |
The University of Texas Health Science Center at San Antonio |
2024-11-07 | PHASE3 |
| NCT06946628 | NOT_YET_RECRUITING | Diabetes Mellitus |
Sun Yat-sen University |
2025-06-01 | PHASE3 |
| NCT05946564 | RECRUITING | ANCA Associated Vasculitis; Rapidly Progressive Glomerulonephritis; Crescentic Glomerulonephritis |
Assistance Publique - Hôpitaux de Paris |
2023-10-24 | PHASE3 |
| NCT06336798 | RECRUITING | Pulmonary Hypertension; Pulmonary Hypertension Due to Lung Diseases |
Emory University |
2024-12-17 | PHASE2 |
| NCT02889003 | RECRUITING | Chronic Myeloid Leukemia (CML) |
Versailles Hospital |
2016-12 | PHASE2 |
| NCT04501406 | RECRUITING | Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Steatohepatitis |
University of Florida |
2020-12-15 | PHASE2 |
| NCT07289750 | NOT_YET_RECRUITING | T2DM; MAFLD |
The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
2026-05-01 | PHASE4 |
| NCT05727761 | RECRUITING | Oral Leukoplakia |
University of Minnesota |
2025-01-01 | PHASE2 |
| NCT07056699 | RECRUITING | Type1diabetes |
The University of Texas Health Science Center at San Antonio |
2026-07-01 | PHASE3 |
| NCT07053319 | RECRUITING | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2026-05-11 | PHASE1 |
| NCT07117630 | RECRUITING | Breast Cancer |
Fudan University |
2025-09-25 | PHASE2 |
| NCT06729996 | RECRUITING | Pancreatitis, Chronic; Pancreatitis, Acute; Diabetes Mellitus |
Mayo Clinic |
2025-05-29 | PHASE2 |
| NCT05305287 | RECRUITING | Non-Alcoholic Fatty Liver Disease; Type 2 Diabetes; Mitochondrial Metabolism Disorders |
The University of Texas Health Science Center at San Antonio |
2022-11-01 | PHASE4 |
| NCT03109288 | RECRUITING | Multiple Sclerosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2017-08-11 | PHASE1; PHASE2 |
| NCT06989723 | RECRUITING | Type 2 Diabetes; Fatty Liver |
Seoul National University Bundang Hospital |
2025-01-01 | PHASE4 |
| NCT06399835 | RECRUITING | Type 2 Diabetes |
Seoul National University Bundang Hospital |
2024-02-01 | PHASE4 |
| NCT06135584 | NOT_YET_RECRUITING | Metabolic Dysfunction-associated Fatty Liver Disease; Cirrhosis |
The Affiliated Hospital of Hangzhou Normal University |
2023-11-18 | |
| NCT05753657 | RECRUITING | Metastatic Breast Cancer; Hyperinsulinism; Hyperglycemia Drug Induced |
Rambam Health Care Campus |
2022-12-25 | EARLY_PHASE1 |
| NCT03866408 | RECRUITING | Obesity |
Mayo Clinic |
2018-11-12 | EARLY_PHASE1 |
| NCT07604779 | ACTIVE_NOT_RECRUITING | Polycystic Ovarian Syndrome (PCOS) |
Beni-Suef University |
2026-05-17 | |
| NCT02969798 | RECRUITING | Diabetes Mellitus, Type 2; Impaired Glucose Tolerance (IGT); Impaired Fasting Glucose (IFG) |
The University of Texas Health Science Center at San Antonio |
2014-01-01 | |
| NCT05013255 | RECRUITING | Breast Cancer; Muscle Fatigue |
West Virginia University |
2021-12-23 | PHASE2 |
| NCT06972732 | RECRUITING | Type 2 Diabetes |
Boryung Pharmaceutical Co., Ltd |
2025-06-11 | PHASE4 |
| NCT05501483 | RECRUITING | Type 2 Diabetes |
Karolinska Institutet |
2023-02-08 | |
| NCT06922656 | NOT_YET_RECRUITING | Type 1 Diabetes |
Dasman Diabetes Institute |
2025-09-15 | PHASE4 |
| NCT07083401 | RECRUITING | Diabete Mellitus |
Boryung Pharmaceutical Co., Ltd |
2025-07-05 | PHASE1 |
| NCT07083388 | RECRUITING | Diabetes Mellitus |
Boryung Pharmaceutical Co., Ltd |
2025-07-03 | PHASE1 |
| NCT07444424 | COMPLETED | Healthy Participants |
AstraZeneca |
2026-03-13 | PHASE1 |
| NCT05028140 | RECRUITING | Type II Diabetes |
EMS |
2024-10-08 | PHASE3 |
| NCT06851962 | COMPLETED | Diabetes Mellitus Type 2 |
Fundación para la Investigación del Hospital Clínico de Valencia |
2025-05-26 | PHASE4 |
| NCT07462065 | RECRUITING | Infertility Treatment; Pregnancy Rates |
PAEC General Hospital, Islamabad |
2026-03-01 | PHASE4 |
| NCT06571591 | COMPLETED | T2DM |
Celltrion |
2024-08-27 | PHASE3 |
| NCT03878459 | ACTIVE_NOT_RECRUITING | Type 1 Diabetes Mellitus |
The University of Texas Health Science Center at San Antonio |
2019-08-08 | PHASE4 |
| NCT07180745 | NOT_YET_RECRUITING | Non-alcoholic Fatty Liver Disease NAFLD; Non-alcoholic Steatohepatitis NASH |
Badr University |
2025-11-01 | PHASE4 |
| NCT06875193 | RECRUITING | Type2diabetes |
Dong Wha Pharmaceutical Co. Ltd. |
2024-05-28 | PHASE4 |
| NCT06594172 | NOT_YET_RECRUITING | Radiation Disease; Cognitive Impairment; Drug Effect |
Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
2024-09-10 | PHASE2 |
| NCT07472179 | COMPLETED | PCOS(Insulin Resistant) |
Mst.Sumyara Khatun |
2024-08-12 | |
| NCT04843046 | COMPLETED | Cocaine Use Disorder |
The University of Texas Health Science Center, Houston |
2021-08-23 | PHASE2 |
| NCT05875675 | NOT_YET_RECRUITING | Calcification of Aortic Valve; Aortic Valve Stenosis |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2023-07-01 | PHASE2 |
| NCT05919147 | ACTIVE_NOT_RECRUITING | Lung Cancer |
Pennington Biomedical Research Center |
2024-01-03 | PHASE2 |
| NCT04370093 | COMPLETED | Nephrolithiasis, Uric Acid |
University of Texas Southwestern Medical Center |
2019-10-17 | PHASE4 |
| NCT05394142 | UNKNOWN | Polycystic Ovary Syndrome (PCOS) |
Fundació Sant Joan de Déu |
2022-05-24 | PHASE2 |
| NCT04300127 | COMPLETED | Gastroparesis |
Johns Hopkins University |
2019-10-24 | EARLY_PHASE1 |
| NCT03452267 | WITHDRAWN | Insulin Sensitivity |
Wayne State University |
2019-09-01 | PHASE2; PHASE3 |
| NCT06107153 | COMPLETED | Type2diabetes |
University of Basrah |
2023-11-01 | PHASE3 |
| NCT07083232 | COMPLETED | Diabetic; Myocardial Infarction |
Al-Azhar University |
2024-10-30 | PHASE4 |
| NCT04794127 | COMPLETED | Liposarcoma, Myxoid; Liposarcoma, Dedifferentiated; Liposarcoma, Round Cell |
Mario Negri Institute for Pharmacological Research |
2022-02-02 | PHASE2 |
| NCT04271189 | COMPLETED | Newly Diagnosed Type 2 Diabetes |
Azienda Ospedaliero-Universitaria di Parma |
2020-09-01 | PHASE3 |
| NCT05107765 | COMPLETED | Alcohol Use Disorder |
The University of Texas Health Science Center, Houston |
2022-05-12 | PHASE1; PHASE2 |
| NCT05775380 | UNKNOWN | Myocardial Reperfusion Injury |
University of Campinas, Brazil |
2023-06-15 | PHASE4 |
| NCT05942963 | UNKNOWN | Non-Alcoholic Fatty Liver Disease; Type2diabetes |
Jinnah Postgraduate Medical Centre |
2023-10 | PHASE4 |
| NCT03864146 | COMPLETED | Alcohol Use Disorder |
VA Office of Research and Development |
2019-07-17 | |
| NCT02852486 | COMPLETED | Leukemia, Chronic Myeloid |
University of Campinas, Brazil |
2016-06-22 | PHASE2 |
| NCT05254626 | COMPLETED | Non-alcoholic Steatohepatitis |
Cairo University |
2022-08-01 | PHASE2 |
| NCT03499704 | COMPLETED | Diabetes Mellitus, Type 2 |
Celltrion Pharm, Inc. |
2020-02-11 | PHASE4 |
| NCT05659459 | TERMINATED | COVID-19 |
Kinarus AG |
2022-08-25 | PHASE2 |
| NCT02879409 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus Type 2 |
Weill Cornell Medical College in Qatar |
2016-11 | |
| NCT05760677 | UNKNOWN | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; T2D |
Affiliated Hospital of Nantong University |
2022-10-01 | PHASE1 |
| NCT03720366 | COMPLETED | Leukemia, Myeloid, Acute |
Celgene |
2018-10-04 | PHASE1 |
| NCT04419337 | UNKNOWN | Diabetes Mellitus; Stroke |
Chang Gung Memorial Hospital |
2019-09-15 | PHASE2 |
| NCT06164665 | COMPLETED | High Altitude |
United States Army Research Institute of Environmental Medicine |
2023-03-01 | PHASE4 |
| NCT05946564 | Not yet recruiting | ANCA Associated Vasculitis|Rapidly Progressive Glomerulonephritis|Crescentic Glomerulonephritis |
Assistance Publique - Hôpitaux de Paris|Ministry of Health France |
2023-07 | Phase 3 |
| NCT05629806 | UNKNOWN | Type 2 Diabetes; Blood Glucose Fluctuation |
Nanjing First Hospital, Nanjing Medical University |
2022-04-10 | PHASE3 |
| NCT04976283 | UNKNOWN | Diabetes Mellitus, Type 2; NASH - Nonalcoholic Steatohepatitis; NAFLD |
Getz Pharma |
2021-09-15 | PHASE4 |
| NCT05605158 | UNKNOWN | Non Alcoholic Steatohepatitis |
Tanta University |
2022-11 | PHASE3 |
| NCT04658849 | WITHDRAWN | Insulin Resistance; Prostate Cancer |
St. Louis University |
2020-12-02 | EARLY_PHASE1 |
| NCT01107717 | COMPLETED | Diabetes |
The University of Texas Health Science Center at San Antonio |
2009-01 | PHASE4 |
| NCT05473806 | UNKNOWN | Hepatitis B, Chronic; Fibrosis, Liver; Diabetes Mellitus, Type 2 |
Seung Up Kim |
2020-09-18 | PHASE4 |
| NCT04995978 | WITHDRAWN | Prostate Cancer; Insulin Resistance |
St. Louis University |
2021-12-01 | PHASE2 |
| NCT05519813 | UNKNOWN | Polycystic Ovary Syndrome |
Bing He |
2022-01-01 | PHASE4 |
| NCT05422092 | UNKNOWN | Type 2 Diabetes Mellitus With Complication |
First Affiliated Hospital Xi'an Jiaotong University |
2022-09-20 | |
| NCT05591235 | UNKNOWN | Type2diabetes; Insulin Resistance |
Nanjing First Hospital, Nanjing Medical University |
2022-11 | PHASE3 |
| NCT04662866 | UNKNOWN | Impaired Glucose Tolerance; Insulin Sensitivity; Glucose Metabolism Disorders |
Oslo University Hospital |
2021-02-10 | PHASE2 |
| NCT02767063 | UNKNOWN | Leukemia, Myeloid, Chronic-Phase |
Versailles Hospital |
2016-07 | PHASE1; PHASE2 |
| NCT05305287 | Recruiting | Non-Alcoholic Fatty Liver Disease|Type 2 Diabetes|Mitochondrial Metabolism Disorders |
The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2022-11-01 | Phase 4 |
| NCT04657939 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Leeds |
2020-12-01 | PHASE4 |
| NCT02535832 | COMPLETED | Rheumatoid Arthritis; Insulin Resistance |
Ohio State University |
2015-09 | PHASE1 |
| NCT04885712 | COMPLETED | Type2 Diabetes |
Boryung Pharmaceutical Co., Ltd |
2021-05-28 | PHASE3 |
| NCT03646292 | COMPLETED | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes; Digestive System Disease; Liver Diseases; Fatty Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-Alcoholic Fatty Liver Disease; Hypoglycemic Agents; Physiological Effects of Drugs; Sodium-Glucose Cotransporter 2 Inhibitors; Pioglitazone; Molecular Mechanisms of Pharmacological Action; Empagliflozin; Thiazolidinediones |
Yonsei University |
2018-12-06 | PHASE4 |
| NCT04584242 | UNKNOWN | Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes |
Yonsei University |
2020-09-03 | PHASE4 |
| NCT05411965 | Completed | Diabetes Mellitus Type 2 |
Boryung Pharmaceutical Co. Ltd |
2022-04-28 | Phase 1 |
| NCT02315287 | UNKNOWN | Type 2 Diabetes |
Seoul National University Bundang Hospital |
2014-09 | PHASE4 |
| NCT04535700 | COMPLETED | Type 2 Diabetes |
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
2020-09-18 | PHASE4 |
| NCT03794518 | UNKNOWN | Risk Reduction |
Hamad Medical Corporation |
2019-03 | PHASE3 |
| NCT04867252 | COMPLETED | PCOS |
Khyber Medical University Peshawar |
2021-05-03 | PHASE2 |
| NCT02823808 | UNKNOWN | Diabetes |
Kyunghee University Medical Center |
2017-07 | PHASE4 |
| NCT04604223 | UNKNOWN | Covid19; Type 2 Diabetes |
Dasman Diabetes Institute |
2021-01-18 | PHASE4 |
| NCT04883125 | COMPLETED | Chronic Myelogenous Leukemia, BCR-ABL Positive; CML, Chronic Phase |
Mansoura University |
2018-01-01 | PHASE2 |
| NCT04123067 | TERMINATED | Stroke, Acute; Hyperglycemia; Diabetes |
Milton S. Hershey Medical Center |
2020-09-01 | PHASE1; PHASE2 |
| NCT04287387 | UNKNOWN | Type2 Diabetes Mellitus |
Peking Union Medical College Hospital |
2020-03-02 | PHASE4 |
| NCT03566225 | COMPLETED | Pioglitazone |
Ain Shams University |
2018-01-30 | EARLY_PHASE1 |
| NCT05521633 | COMPLETED | NAFLD |
King Edward Medical University |
2019-06-06 | PHASE3 |
| NCT02653209 | COMPLETED | Type 2 Diabetes |
Royal Devon and Exeter NHS Foundation Trust |
2016-11-01 | PHASE4 |
| NCT03440034 | COMPLETED | Myositis; Inclusion Body Myositis; Muscular Diseases; Musculoskeletal Disease; Neuromuscular Diseases; Nervous System Diseases |
Johns Hopkins University |
2018-05-22 | PHASE1 |
| NCT03950505 | UNKNOWN | Non-alcoholic Steatohepatitis; Type2 Diabetes |
Yonsei University |
2020-05-29 | PHASE4 |
| NCT04501406 | Recruiting | Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis |
University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2020-12-15 | Phase 2 |
| NCT04473274 | COMPLETED | Coronavirus Infection; Diabetes |
Samaritan Health Services |
2020-05-21 | PHASE4 |
| NCT04392557 | UNKNOWN | Diabetes Mellitus, Type 2 |
University of Catanzaro |
2020-07-01 | PHASE4 |
| NCT04535700 | Completed | Type 2 Diabetes |
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
2020-09-18 | Phase 4 |
| NCT02338999 | COMPLETED | Systemic Lupus Erythematosus |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
2015-06-18 | PHASE1; PHASE2 |
| NCT03910361 | COMPLETED | Type2 Diabetes; Non-Alcoholic Fatty Liver Disease |
Dong-A ST Co., Ltd. |
2019-04-12 | PHASE4 |
| NCT02942758 | TERMINATED | Acute Myeloid Leukemia |
University Hospital Regensburg |
2017-04-10 | PHASE2 |
| NCT04113889 | COMPLETED | PCOS |
Khyber Medical University Peshawar |
2019-10-15 | PHASE2 |
| NCT03060772 | TERMINATED | Alcoholism |
Emory University |
2018-01-03 | PHASE2 |
| NCT03471117 | TERMINATED | Chronic Kidney Diseases |
The University of Texas at Arlington |
2018-04-01 | PHASE4 |
| NCT03080480 | TERMINATED | Chronic Granulomatous Disease |
Children's Hospital of Fudan University |
2017-09-01 | PHASE1; PHASE2 |
| NCT02697617 | COMPLETED | Polycystic Kidney Disease |
Indiana University |
2016-01-26 | PHASE2 |
| NCT00904046 | Recruiting | Uric Acid Kidney Stone Disease |
University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc. |
2019-09-05 | Not Applicable |
| NCT02917629 | TERMINATED | Oral Cavity Neoplasm; Oropharyngeal Neoplasm; Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7; Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 |
National Cancer Institute (NCI) |
2018-05-31 | PHASE2 |
| NCT03860753 | TERMINATED | Alcohol Use Disorder |
The University of Texas Health Science Center, Houston |
2019-03-01 | PHASE1; PHASE2 |
| NCT02852083 | UNKNOWN | Squamous Cell Lung Cancer; Non-Squamous Cell Lung Cancer; Non-Small Cell Lung Cancer |
University Hospital Regensburg |
2016-01 | PHASE2 |
| NCT04470310 | UNKNOWN | Type 2 Diabetes Mellitus |
Seoul National University Hospital |
2015-12-31 | PHASE4 |
| NCT03796975 | COMPLETED | Type 2 Diabetes Mellitus; Non-alcoholic Fatty Liver Disease; Efficacy |
Xijing Hospital |
2018-06-28 | PHASE4 |
| NCT03231033 | COMPLETED | Autoimmune Pulmonary Alveolar Proteinosis |
Children's Hospital Medical Center, Cincinnati |
2017-08-17 | PHASE1 |
| NCT03864523 | COMPLETED | Adrenomyeloneuropathy; X-linked Adrenoleukodystrophy |
Pujol, Aurora, M.D. |
2016-01 | PHASE2 |
| NCT02919176 | COMPLETED | Obese; Metabolic Syndrome |
Philip Kern |
2016-09-01 | EARLY_PHASE1 |
| NCT02763007 | TERMINATED | Diabetes Mellitus, Type 2 |
Kun-Ho Yoon |
2016-05-18 | PHASE4 |
| NCT03757923 | UNKNOWN | Menstrual Irregularities; Hyperandrogenism |
Dow University of Health Sciences |
2018-06-18 | PHASE1; PHASE2 |
| NCT04671056 | COMPLETED | Healthy |
Madrigal Pharmaceuticals, Inc. |
2018-11-09 | PHASE1 |
| NCT00700856 | UNKNOWN | Type 2 Diabetes Mellitus; Cardiovascular Disease |
Italian Society of Diabetology |
2008-09 | PHASE4 |
| NCT01471808 | COMPLETED | Diabetes Mellitus, Type 2 |
Sun Yat-sen University |
2011-10 | PHASE4 |
| NCT02689843 | COMPLETED | Polycystic Ovary Syndrome |
Shiraz University of Medical Sciences |
2018-02-01 | EARLY_PHASE1 |
| NCT02231021 | COMPLETED | Type 2 Diabetes Mellitus |
Kun-Ho Yoon |
2014-09 | PHASE4 |
| NCT03196362 | UNKNOWN | Type 2 Diabetes Mellitus |
Sun Yat-sen University |
2016-12-01 | PHASE4 |
| NCT02694263 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Leicester |
2016-07 | PHASE4 |
| NCT01931566 | TERMINATED | Mild Cognitive Impairment Due to Alzheimer's Disease |
Takeda |
2013-08-01 | PHASE3 |
| NCT03501277 | COMPLETED | Healthy Volunteers |
Takeda |
2018-05-26 | PHASE1 |
| NCT03298464 | COMPLETED | Obese |
NGM Biopharmaceuticals, Inc |
2017-09-11 | PHASE1 |
| NCT02347813 | COMPLETED | Squamous Cell Carcinoma of the Skin |
University of Rochester |
2014-11 | PHASE2 |
| NCT03335956 | COMPLETED | Healthy |
Corcept Therapeutics |
2017-09-21 | PHASE1 |
| NCT01135394 | COMPLETED | Type 2 Diabetes |
University of Maryland, Baltimore |
2009-03 | |
| NCT02787551 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2016-07-06 | PHASE3 |
| NCT03457597 | COMPLETED | Healthy |
Corcept Therapeutics |
2018-03-06 | PHASE1 |
| NCT02585765 | WITHDRAWN | Spinal Cord Injury; Pressure Ulcers |
James J. Peters Veterans Affairs Medical Center |
2017-02-01 | PHASE2 |
| NCT02284906 | TERMINATED | Mild Cognitive Impairment Due to Alzheimer's Disease |
Takeda |
2015-02-12 | PHASE3 |
| NCT00904046 | COMPLETED | Uric Acid Kidney Stone Disease |
University of Texas Southwestern Medical Center |
2010-01-15 | |
| NCT02303405 | TERMINATED | Diabetes Mellitus Type 2 With Hyperglycemia |
Charles Drew University of Medicine and Science |
2014-11 | PHASE2 |
| NCT01838317 | COMPLETED | Cancer of the Pancreas |
University of Texas Southwestern Medical Center |
2013-05 | PHASE2 |
| NCT02733679 | COMPLETED | Ataxia-Telangiectasia |
NHS Tayside |
2016-09-29 | PHASE4 |
| NCT03117517 | COMPLETED | Polycystic Ovarian Syndrome |
Khyber Medical University Peshawar |
2017-03-20 | EARLY_PHASE1 |
| NCT02429232 | UNKNOWN | Osteoporosis; Diabetes Mellitus |
National Taiwan University Hospital |
2015-10 | PHASE4 |
| NCT02875821 | COMPLETED | Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD) |
Yonsei University |
2016-04-26 | PHASE4 |
| NCT02887625 | UNKNOWN | Type 2 Diabetes |
Dr. Muhammad Abdulghani |
2015-02 | |
| NCT03125694 | COMPLETED | Uncontrolled Type 2 Diabetes Mellitus |
Tehran University of Medical Sciences |
2015-02-01 | PHASE3 |
| NCT00212004 | TERMINATED | Diabetes Mellitus; Myocardial Infarction |
National Cerebral and Cardiovascular Center, Japan |
2005-04 | PHASE4 |
| NCT01655719 | COMPLETED | Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene |
University of Michigan |
2012-04 | PHASE2 |
| NCT02365233 | TERMINATED | Type II Diabetes; Nonalcoholic Fatty Liver |
The University of Texas Medical Branch, Galveston |
2013-05-01 | PHASE4 |
| NCT01748994 | COMPLETED | Obesity; Metabolic Syndrome |
Pennington Biomedical Research Center |
2011-02 | |
| NCT02592317 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms, Castration-Resistant |
Aragon Pharmaceuticals, Inc. |
2016-02-12 | PHASE1 |
| NCT02687425 | UNKNOWN | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
Meng Li |
2016-02 | PHASE2 |
| NCT02753803 | COMPLETED | Type 2 Diabetes |
Dong-A ST Co., Ltd. |
2016-07-27 | PHASE1 |
| NCT01972724 | COMPLETED | Type II Diabetes Mellitus |
Takeda |
2013-12-16 | PHASE4 |
| NCT01002547 | COMPLETED | Nonalcoholic Steatohepatitis |
VA Office of Research and Development |
2010-06-24 | PHASE4 |
| NCT02195791 | TERMINATED | Stroke |
Taipei Medical University Shuang Ho Hospital |
2014-07 | PHASE2 |
| NCT00994175 | COMPLETED | Severe, Refractory Asthma; Airway Inflammation; Airflow Obstruction |
National Heart, Lung, and Blood Institute (NHLBI) |
2009-09-23 | PHASE2 |
| NCT00780234 | COMPLETED | Lung Cancer; Endobronchial Dysplasia |
VA Office of Research and Development |
2009-08 | PHASE2 |
| NCT01352182 | COMPLETED | Severe Sepsis; Septic Shock |
Children's Hospital Medical Center, Cincinnati |
2011-10 | PHASE1; PHASE2 |
| NCT02133625 | COMPLETED | Advanced Solid Tumor; Metastatic Solid Tumor |
Dana-Farber Cancer Institute |
2011-08 | PHASE1 |
| NCT01717040 | TERMINATED | Bipolar Disorder; Insulin Resistance |
University Hospitals Cleveland Medical Center |
2012-09 | PHASE4 |
| NCT01301027 | COMPLETED | End Stage Renal Disease |
University of Utah |
2008-05 | |
| NCT02426294 | UNKNOWN | Type 2 Diabetes Mellitus |
Pusan National University Hospital |
2015-02 | PHASE4 |
| NCT00091949 | COMPLETED | Stroke; Myocardial Infarction; Diabetes |
Yale University |
2005-02 | PHASE3 |
| NCT02072096 | TERMINATED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2014-02 | PHASE4 |
| NCT02142309 | UNKNOWN | Type 2 Diabetes |
University of Campania Luigi Vanvitelli |
2005-10 | PHASE4 |
| NCT01631630 | TERMINATED | Alcohol Dependence; Alcohol Drinking; Stress; Alcohol-Related Disorders |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
2012-05 | PHASE2 |
| NCT02265276 | UNKNOWN | Fatty Liver |
Command Hospital, India |
2014-10 | PHASE3 |
| NCT01205282 | COMPLETED | Autism Spectrum Disorders |
Evdokia Anagnostou |
2013-04 | PHASE2 |
| NCT02371603 | COMPLETED | Anaemia |
GlaxoSmithKline |
2015-02-11 | PHASE1 |
| NCT02473627 | COMPLETED | Healthy |
Daiichi Sankyo |
2015-05 | PHASE1 |
| NCT01947790 | COMPLETED | LVM; Type 2 Diabetic Patients With IHD; Endothelial Function |
Xiang Guang-da |
2013-09 | PHASE4 |
| NCT02341703 | COMPLETED | Polycystic Ovary Syndrome; Infertility |
Cairo University |
2015-02 | EARLY_PHASE1 |
| NCT00427999 | COMPLETED | Prostate Cancer |
Novartis Pharmaceuticals |
2007-02 | PHASE2 |
| NCT02683226 | COMPLETED | Polycystic Ovary Syndrome; Insulin Resistance |
University Medical Centre Ljubljana |
2015-03 | PHASE4 |
| NCT02774343 | COMPLETED | Cocaine Use Disorder; Alcohol Use Disorder |
The University of Texas Health Science Center, Houston |
2012-08 | PHASE1; PHASE2 |
| NCT02342067 | COMPLETED | Healthy |
Tobira Therapeutics, Inc. |
2014-12 | PHASE1 |
| NCT00815399 | COMPLETED | Type 2 Diabetes |
University of Campania Luigi Vanvitelli |
2007-10 | PHASE4 |
| NCT01517165 | TERMINATED | Opioid-Related Disorders |
National Institute on Drug Abuse (NIDA) |
2012-01-04 | PHASE1 |
| NCT03030300 | COMPLETED | Type2 Diabetes |
Qianfoshan Hospital |
2008-01 | PHASE4 |
| NCT00994682 | COMPLETED | Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver Disease; Type 2 Diabetes Mellitus |
University of Florida |
2008-12 | PHASE4 |
| NCT02222441 | COMPLETED | Healthy |
Pfizer |
2014-10 | PHASE1 |
| NCT01817400 | COMPLETED | Infertility, Female; Obesity |
University of Colorado, Denver |
2013-03 | EARLY_PHASE1 |
| NCT02236962 | UNKNOWN | Type 2 Diabetes; Obesity; Cardiovascular Disease |
Bayside Health |
2012-04 | |
| NCT00745225 | COMPLETED | End-stage Renal Disease |
The University of Hong Kong |
2006-02 | PHASE4 |
| NCT01703260 | TERMINATED | Nonalcoholic Steatohapatitis |
AstraZeneca |
2013-06 | PHASE2 |
| NCT01151670 | COMPLETED | Brain Neoplasms, Malignant; Brain Neoplasms, Benign; Malignant Meningioma; Glioblastoma Multiforme; Anaplastic Astrocytoma |
Wake Forest University Health Sciences |
2010-08 | PHASE1 |
| NCT02192684 | COMPLETED | Insulin Sensitivity; Obstructive Sleep Apnea |
Stanford University |
2010-09 | |
| NCT03011775 | COMPLETED | Adverse Effect; Atherosclerosis, Coronary; Insulin Resistance Syndrome |
Ukrainian Medical Stomatological Academy |
2012-11 | PHASE4 |
| NCT01895569 | UNKNOWN | Type 2 Diabetes Mellitus |
University of Pavia |
2013-06 | PHASE4 |
| NCT01614301 | UNKNOWN | Advanced Melanoma |
University of Regensburg |
2012-05 | PHASE1; PHASE2 |
| NCT01280123 | COMPLETED | Parkinson's Disease |
University of Rochester |
2011-03 | PHASE2 |
| NCT01395797 | TERMINATED | Heroin Dependence; Nicotine Dependence |
New York State Psychiatric Institute |
2011-03 | PHASE1; PHASE2 |
| NCT00951379 | TERMINATED | Oral Leukoplakia |
National Cancer Institute (NCI) |
2010-02 | PHASE2 |
| NCT01174056 | COMPLETED | Lung Inflammation |
Washington University School of Medicine |
2011-07 | EARLY_PHASE1 |
| NCT01909141 | COMPLETED | Polycystic Ovary Syndrome; Infertility |
Cairo University |
2013-08 | EARLY_PHASE1 |
| NCT01157975 | WITHDRAWN | Hepatitis C |
University of California, San Diego |
2008-10 | PHASE2 |
| NCT01559857 | COMPLETED | Major Depressive Disorder; Insulin Resistance |
Stanford University |
2011-11 | PHASE4 |
| NCT01695707 | WITHDRAWN | Atopic Dermatitis |
University of Rochester |
2013-03 | |
| NCT01935804 | COMPLETED | Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders |
King Abdulaziz University |
2009-01 | PHASE2 |
| NCT01395784 | COMPLETED | Opioid Abuse |
New York State Psychiatric Institute |
2010-08 | PHASE2 |
| NCT00855010 | COMPLETED | Obesity; Type 2 Diabetes |
University of Texas Southwestern Medical Center |
2009-02 | |
| NCT02099838 | COMPLETED | Diabetes Mellitus, Type 2 |
Huazhong University of Science and Technology |
2012-01 | PHASE4 |
| NCT00736996 | COMPLETED | Mild Cognitive Impairment |
University of Colorado, Denver |
2008-11 | PHASE2 |
| NCT00782795 | COMPLETED | Chronic Pancreatitis; Insulin Resistance; Normal or Mildly Abnormal Stool Fat Levels |
University of Michigan |
2008-11 | PHASE2 |
| NCT01010243 | UNKNOWN | Multiple Myeloma |
University of Regensburg |
2009-10 | PHASE1; PHASE2 |
| NCT00745914 | COMPLETED | Endstage Renal Disease; Diabetes |
The University of Hong Kong |
2008-09 | |
| NCT01289639 | TERMINATED | Fatty Liver |
VA Office of Research and Development |
2005-10 | |
| NCT01186250 | COMPLETED | Cardiac Allograft Vasculopathy |
Stanford University |
2010-07 | PHASE2 |
| NCT01454336 | COMPLETED | Liver Fibrosis |
Royan Institute |
2010-06 | PHASE1 |
| NCT01873001 | COMPLETED | Healthy Volunteers |
Janssen Research & Development, LLC |
2013-05 | PHASE1 |
| NCT00787644 | TERMINATED | Asthma; Obesity |
University of Vermont |
2009-01 | PHASE2 |
| NCT01819402 | UNKNOWN | To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging |
Kurume University |
2012-03 | |
| NCT00835120 | COMPLETED | Metabolic Syndrome; Bipolar Depression; Insulin Resistance |
University Hospitals Cleveland Medical Center |
2009-03 | PHASE4 |
| NCT00827892 | COMPLETED | Intracerebral Hemorrhage |
The University of Texas Health Science Center, Houston |
2009-03 | PHASE2 |
| NCT01095666 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2010-06 | PHASE3 |
| NCT00811681 | COMPLETED | Friedreich's Ataxia |
Assistance Publique - Hôpitaux de Paris |
2008-12 | PHASE3 |
| NCT01963663 | COMPLETED | Type 2 Diabetes Mellitus |
Tehran University of Medical Sciences |
2012-11 | |
| NCT01882907 | COMPLETED | Type 2 Diabetes |
Pusan National University Hospital |
2009-12 | PHASE4 |
| NCT00408850 | UNKNOWN | Metabolic Syndrome |
Baker Heart Research Institute |
2008-11 | PHASE3 |
| NCT01183013 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2010-08 | PHASE3 |
| NCT01331967 | COMPLETED | Diabetic Stable Angina; Diabetic Unstable Angina |
Korea University Anam Hospital |
2011-02 | PHASE4 |
| NCT00742326 | TERMINATED | HIV; Hepatitis C; Liver Disease; Fatty Liver; Steatosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2008-08 | PHASE4 |
| NCT00470262 | COMPLETED | Metabolic Syndrome X; Prediabetic State |
VA Office of Research and Development |
2007-01 | |
| NCT01175486 | UNKNOWN | Diabetes |
Taipei Veterans General Hospital, Taiwan |
2010-07 | PHASE4 |
| NCT01339143 | UNKNOWN | Diabetes Mellitus; Oxidative Stress |
Korea University Anam Hospital |
2010-04 | PHASE4 |
| NCT02292290 | COMPLETED | Type 2 Diabetes |
University of Leicester |
2011-04 | PHASE4 |
| NCT01025765 | UNKNOWN | Chronic Hepatitis C |
National Taiwan University Hospital |
2009-11 | PHASE4 |
| NCT00399204 | WITHDRAWN | Type 2 Diabetes |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2006-01 | PHASE4 |
| NCT01342770 | TERMINATED | Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2011-04 | PHASE2 |
| NCT01175824 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2011-04 | PHASE4 |
| NCT00554853 | COMPLETED | Rheumatoid Arthritis |
University of Michigan |
2007-11 | PHASE3 |
| NCT01431521 | COMPLETED | Non-alcoholic Fatty Liver Disease |
Merck Sharp & Dohme LLC |
2011-10-26 | PHASE1 |
| NCT00763139 | COMPLETED | Rheumatoid Arthritis |
Vanderbilt University |
2009-04 | |
| NCT01147627 | COMPLETED | Diabetes Mellitus, Type 2; Newly Diagnosed |
Sun Yat-sen University |
2010-08 | |
| NCT00927290 | TERMINATED | Chronic Hepatitis C; Insulin Resistance |
French National Agency for Research on AIDS and Viral Hepatitis |
2009-12-03 | PHASE3 |
| NCT01456117 | COMPLETED | Healthy |
Takeda |
2011-11 | PHASE1 |
| NCT01043029 | COMPLETED | Diabetes Mellitus Type 2 |
Hoffmann-La Roche |
2010-05 | PHASE2 |
| NCT00789750 | COMPLETED | Type 2 Diabetes Mellitus |
Daiichi Sankyo |
2009-04 | PHASE3 |
| NCT01341730 | TERMINATED | Atherosclerosis; Coronary Artery Disease |
The Catholic University of Korea |
2011-06 | PHASE4 |
| NCT00545857 | COMPLETED | Type 1 Diabetes Mellitus |
Stony Brook University |
2002-06 | PHASE1 |
| NCT01184144 | WITHDRAWN | Endometriosis |
University of Wisconsin, Madison |
2010-08 | PHASE2; PHASE3 |
| NCT01225081 | COMPLETED | Type 2 Diabetes Mellitus |
Astellas Pharma Inc |
2010-09-15 | PHASE3 |
| NCT01210001 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2010-09 | PHASE3 |
| NCT01106131 | COMPLETED | Type 2 Diabetes Mellitus |
Chong Kun Dang Pharmaceutical |
2010-05 | PHASE3 |
| NCT00634036 | COMPLETED | Asthma |
Fernando Holguin |
2009-10 | PHASE2 |
| NCT02027103 | COMPLETED | Type 2 Diabetes Mellitus |
Tehran University of Medical Sciences |
2012-01 | |
| NCT00996658 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2009-10 | PHASE3 |
| NCT00953498 | COMPLETED | Type 2 Diabetes |
Centre Hospitalier Universitaire Dijon |
2007-10 | PHASE4 |
| NCT01570660 | COMPLETED | Type 2 Diabetes Mellitus |
German Diabetes Center |
2002-02 | |
| NCT01911728 | COMPLETED | Pharmacokinetics of MDV3100; Castration Resistant Prostate Cancer (CRPC) |
Astellas Pharma Europe B.V. |
2011-07-25 | PHASE1 |
| NCT02888964 | COMPLETED | Leukemia, Myeloid, Chronic-Phase |
Versailles Hospital |
2009-12 | PHASE2 |
| NCT00867126 | TERMINATED | Pancreatic Cancer |
University of Texas Southwestern Medical Center |
2009-03-02 | EARLY_PHASE1 |
| NCT01217073 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-10-08 | PHASE2 |
| NCT00839527 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-02 | PHASE3 |
| NCT01322308 | COMPLETED | Systemic Lupus Erythematosus |
National Heart Institute, Mexico |
2007-03 | PHASE4 |
| NCT01588470 | COMPLETED | Type 2 Diabetes; Coronary Heart Disease |
The University of Texas Health Science Center at San Antonio |
2006-06 | PHASE4 |
| NCT00232583 | COMPLETED | Type 2 Diabetes Mellitus |
University of Texas Southwestern Medical Center |
2003-11 | |
| NCT01006018 | TERMINATED | Prediabetic State |
Emory University |
2011-07 | |
| NCT01223196 | COMPLETED | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2009-08 | PHASE4 |
| NCT01289119 | COMPLETED | Diabetes Mellitus, Type 2 |
Takeda |
2010-12 | PHASE3 |
| NCT01489943 | COMPLETED | Crohn's Disease |
GlaxoSmithKline |
2011-09-19 | PHASE1 |
| NCT01103414 | COMPLETED | Type 2 Diabetes |
Metabolic Solutions Development Company |
2010-09 | PHASE2 |
| NCT01346254 | COMPLETED | Impaired Glucose Tolerance; Kidney Transplantation |
Marcus Saemann |
2009-12 | PHASE2 |
| NCT01106690 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2010-06 | PHASE3 |
| NCT00849056 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-01 | PHASE3 |
| NCT00846716 | UNKNOWN | Type 2 Diabetes Mellitus |
Shiga University |
2008-03 | |
| NCT01064687 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2010-02 | PHASE3 |
| NCT01195090 | COMPLETED | Type 2 Diabetes |
Sung-Chen Liu |
2009-10 | PHASE4 |
| NCT01109030 | COMPLETED | Major Depressive Disorder |
Tehran University of Medical Sciences |
2010-04 | PHASE2; PHASE3 |
| NCT01040819 | COMPLETED | Type 2 Diabetes Mellitus |
Baylor College of Medicine |
2010-02 | PHASE4 |
| NCT01593371 | COMPLETED | Type 2 Diabetes Mellitus |
Tehran University of Medical Sciences |
2011-07 | |
| NCT02305069 | COMPLETED | Obesity; Sarcopenia |
University of Nottingham |
2009-10 | |
| NCT00671515 | COMPLETED | Depressive Disorder, Major; Metabolic Syndrome X |
Joseph Calabrese, MD |
2008-04 | PHASE2 |
| NCT00633282 | COMPLETED | Nonalcoholic Fatty Liver Disease |
Xin Gao |
2008-03 | PHASE2 |
| NCT01076075 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-06-03 | PHASE3 |
| NCT00179400 | COMPLETED | Type 2 Diabetes Mellitus |
Albert Einstein College of Medicine |
2000-12 | PHASE4 |
| NCT00694759 | COMPLETED | Polycystic Ovary Syndrome |
Oregon Health and Science University |
2006-10 | |
| NCT01253928 | UNKNOWN | ESRD |
Centre Hospitalier Universitaire Vaudois |
2007-03 | PHASE4 |
| NCT01230749 | COMPLETED | Diabetes Mellitus, Type 2 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2010-12 | PHASE2 |
| NCT00926614 | COMPLETED | Hepatitis c |
Brooke Army Medical Center |
2008-09 | PHASE4 |
| NCT00763815 | COMPLETED | Diabetes Mellitus Type 2 |
Sanofi |
2008-09 | PHASE3 |
| NCT01280695 | COMPLETED | Diabetes Mellitus, Type 2 |
Metabolic Solutions Development Company |
2011-02 | PHASE2 |
| NCT00868140 | TERMINATED | Polycystic Ovary Syndrome |
Virginia Commonwealth University |
2009-02 | |
| NCT01026194 | COMPLETED | Type 2 Diabetes Mellitus |
Tanabe Pharma Corporation |
2009-12 | PHASE3 |
| NCT00665353 | COMPLETED | HIV-1 and Hepatitis C Co-Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2009-03 | PHASE2 |
| NCT00843791 | TERMINATED | Obesity; Insulin Resistance |
Oregon Health and Science University |
2009-02 | |
| NCT01276327 | COMPLETED | Healthy |
Boehringer Ingelheim |
2011-01 | PHASE1 |
| NCT00362440 | COMPLETED | HIV Lipodystrophy |
Beth Israel Deaconess Medical Center |
2006-08 | PHASE2 |
| NCT00770835 | COMPLETED | Diabetes Mellitus |
Takeda |
2009-03 | PHASE4 |
| NCT00708175 | COMPLETED | Bone Metabolism |
Takeda |
2008-05 | PHASE4 |
| NCT00376870 | UNKNOWN | Coronary Atherosclerosis; Coronary Restenosis; Diabetes |
University of Rome Tor Vergata |
2008-07 | PHASE3 |
| NCT00736099 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2008-08 | PHASE3 |
| NCT00775164 | WITHDRAWN | Obesity; Insulin Resistance |
University of Minnesota |
2009-01 | PHASE4 |
| NCT00885352 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2009-04-15 | PHASE3 |
| NCT00153166 | COMPLETED | Arterial Occlusive Disease; Intermittent Claudication; Insulin Resistance |
Brigham and Women's Hospital |
2004-01 | PHASE2; PHASE3 |
| NCT00744367 | COMPLETED | Diabetes Mellitus Type 2 |
Hoffmann-La Roche |
2008-10 | PHASE3 |
| NCT00656864 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Vermont |
2008-05 | PHASE4 |
| NCT00879970 | TERMINATED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-05 | PHASE4 |
| NCT00972283 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-09-01 | PHASE3 |
| NCT00722371 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-09-05 | PHASE3 |
| NCT01028963 | COMPLETED | Type 2 Diabetes Mellitus |
Amgen |
2010-01 | PHASE2 |
| NCT00927355 | COMPLETED | Osteoblast; Adipocytes; Bone Density; Osteocalcin; Adiponectin; Mesenchymal Stem Cells |
Emory University |
2009-04 | |
| NCT01115712 | COMPLETED | Healthy; Overweight; Obesity |
Merck Sharp & Dohme LLC |
2010-05 | PHASE1 |
| NCT01156597 | COMPLETED | Type 2 Diabetes Mellitus |
University of Miami |
2008-04 | PHASE3 |
| NCT01009580 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2009-11-05 | PHASE3 |
| NCT00443755 | COMPLETED | Type 2 Diabetes; Insulin Resistance; Metabolic Syndrome |
Mayo Clinic |
2005-08 | PHASE2 |
| NCT00300365 | COMPLETED | Metabolic Syndrome |
University of Pennsylvania |
2005-11 | PHASE2 |
| NCT00970424 | TERMINATED | Diabetes Mellitus, Type II |
Forest Laboratories |
2009-08 | PHASE3 |
| NCT01089790 | TERMINATED | Diabetes Mellitus, Type 2 |
Forest Laboratories |
2010-03 | PHASE3 |
| NCT00676338 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2008-11 | PHASE3 |
| NCT00845182 | COMPLETED | Type 2 Diabetes; Healthy; Impaired Glucose Tolerance |
The University of Texas Health Science Center at San Antonio |
2007-06 | PHASE4 |
| NCT00770445 | COMPLETED | Diabetes Mellitus |
Takeda |
2008-05 | PHASE4 |
| NCT02172235 | COMPLETED | Healthy |
Boehringer Ingelheim |
2010-04 | PHASE1 |
| NCT00690118 | TERMINATED | Amyotrophic Lateral Sclerosis |
University of Ulm |
2008-05 | PHASE2 |
| NCT00991055 | UNKNOWN | Type 2 Diabetes |
National Cheng-Kung University Hospital |
2008-05 | PHASE4 |
| NCT00861341 | COMPLETED | Diabetes; Platelet Function; Healthy |
University of Rochester |
2008-12 | PHASE2 |
| NCT00770640 | COMPLETED | Diabetes Mellitus |
Takeda |
2008-08 | PHASE2 |
| NCT01023620 | COMPLETED | HIV Infections |
University of Texas Southwestern Medical Center |
2009-10 | |
| NCT00825266 | TERMINATED | Hypertension, Pulmonary |
Stanford University |
2008-09 | PHASE2 |
| NCT01082120 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-02 | PHASE1 |
| NCT00220961 | COMPLETED | Impaired Glucose Tolerance; Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2004-01 | PHASE3 |
| NCT00485056 | COMPLETED | Diabetes |
Imperial College London |
2008-04 | PHASE4 |
| NCT01800227 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT01088594 | COMPLETED | Type 2 Diabetes Mellitus |
Solvay Pharmaceuticals |
2010-02 | PHASE1 |
| NCT01800240 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00926016 | COMPLETED | Chronic Hepatitis C |
Brooke Army Medical Center |
2006-06 | |
| NCT00541450 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-01-15 | PHASE3 |
| NCT00231894 | COMPLETED | Diabetes; Schizophrenia; Insulin Resistance; Cognitive Impairment |
Nathan Kline Institute for Psychiatric Research |
2005-05 | PHASE4 |
| NCT00683878 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-07 | PHASE3 |
| NCT00655863 | COMPLETED | Diabetes Mellitus |
Takeda |
2007-07 | PHASE3 |
| NCT00749047 | UNKNOWN | Diabetes Mellitus, Type 2 |
Christchurch Hospital |
2008-09 | PHASE4 |
| NCT01589445 | COMPLETED | Type 2 Diabetes Mellitus |
University of Dhaka |
2008-11 | PHASE4 |
| NCT00770367 | COMPLETED | Diabetes |
Medical University of South Carolina |
2008-10 | PHASE4 |
| NCT02183636 | COMPLETED | Healthy |
Boehringer Ingelheim |
2009-08 | PHASE1 |
| NCT01088919 | COMPLETED | Healthy; Pharmacokinetics of ASP1941 |
Astellas Pharma Inc |
2009-11 | PHASE1 |
| NCT00919555 | COMPLETED | Amyotrophic Lateral Sclerosis |
Phoenix Neurological Associates, LTD |
2008-06 | PHASE1; PHASE2 |
| NCT00680745 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-04 | PHASE3 |
| NCT00604578 | WITHDRAWN | Asthma; Airway Inflammation; Airflow Obstruction; Airway Hyperactivity |
National Heart, Lung, and Blood Institute (NHLBI) |
2008-01-04 | PHASE2 |
| NCT00532935 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-01-26 | PHASE3 |
| NCT00780715 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Dundee |
2008-12 | PHASE4 |
| NCT00507494 | COMPLETED | Diabetes Mellitus; Kidney Transplantation; Proteinuria |
Technische Universität Dresden |
2007-07 | PHASE3 |
| NCT01318122 | COMPLETED | Type 2 Diabetes Mellitus |
Takeda |
2008-05 | PHASE2; PHASE3 |
| NCT00656851 | COMPLETED | HIV Infections; Cardiovascular Disease; Insulin Resistance; HIV Lipodystrophy; The Metabolic Syndrome |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2005-09 | |
| NCT00631007 | COMPLETED | Type 2 Diabetes Mellitus |
InteKrin Therapeutics, Inc. |
2008-02 | PHASE2 |
| NCT00515632 | COMPLETED | Diabetes Mellitus, Type 2 |
Rheoscience A/S |
2007-07 | PHASE3 |
| NCT02276365 | COMPLETED | Healthy |
Boehringer Ingelheim |
2009-06 | PHASE1 |
| NCT00063622 | COMPLETED | Liver Diseases |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2005-01 | PHASE3 |
| NCT01001013 | COMPLETED | Healthy |
LG Life Sciences |
2009-02 | PHASE1 |
| NCT00641043 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2008-03 | PHASE3 |
| NCT00719381 | COMPLETED | Cystic Fibrosis |
Paul Beringer |
2008-01 | PHASE1 |
| NCT00770653 | COMPLETED | Diabetes Mellitus; Dyslipidemias |
Takeda |
2007-04 | PHASE3 |
| NCT00432276 | COMPLETED | Diabetes Mellitus |
Takeda |
2007-01 | PHASE3 |
| NCT00722631 | COMPLETED | Impaired Glucose Tolerance; Type 2 Diabetes Mellitus; Atherosclerosis |
Kurume University |
2007-05 | |
| NCT00722917 | TERMINATED | Diabetes Mellitus |
Takeda |
2008-07 | PHASE2 |
| NCT00511108 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Merck Sharp & Dohme LLC |
2007-07-11 | PHASE1 |
| NCT00484198 | COMPLETED | Type 2 Diabetes Mellitus |
Daiichi Sankyo |
2007-04-23 | PHASE3 |
| NCT00531882 | COMPLETED | Cystic Fibrosis |
University Hospitals Cleveland Medical Center |
2007-09 | |
| NCT00637273 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2008-01 | PHASE3 |
| NCT00771004 | COMPLETED | Oxidative Stress; Coronary Artery Disease; Type 2 Diabetes |
Takeda |
2006-08 | PHASE2 |
| NCT00062764 | COMPLETED | Hepatitis |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2003-06 | PHASE2 |
| NCT01028391 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2007-09-01 | PHASE3 |
| NCT00579813 | COMPLETED | Metabolic Syndrome; Insulin Resistance; Prediabetes |
Philip Kern |
2005-04 | PHASE4 |
| NCT00437970 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Menzies School of Health Research |
2008-04 | PHASE4 |
| NCT00760578 | COMPLETED | Type 2 Diabetes Mellitus |
Metabolic Solutions Development Company |
2008-09 | PHASE2 |
| NCT00586261 | TERMINATED | Chronic Kidney Disease |
Mayo Clinic |
2006-03 | |
| NCT00395941 | COMPLETED | Psoriasis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2006-12 | PHASE2 |
| NCT00681733 | UNKNOWN | Metabolic Parameters and Liver Histology |
Govind Ballabh Pant Hospital |
2007-01 | |
| NCT00639457 | COMPLETED | HIV Infections; Type 2 Diabetes; Obesity; HIV; AIDS; Cardiovascular Disease; Lipodystrophy |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2005-01 | |
| NCT00770952 | COMPLETED | Diabetes Mellitus |
Takeda |
2006-12 | PHASE3 |
| NCT00570622 | COMPLETED | Cirrhosis; Ascites; Portal Hypertension |
Medical University of Vienna |
2004-12 | PHASE4 |
| NCT01318070 | COMPLETED | Type 2 Diabetes Mellitus |
Takeda |
2007-11 | PHASE2; PHASE3 |
| NCT00441272 | COMPLETED | HIV Infections; Hepatic Steatosis; Insulin Resistance |
National Institute of Allergy and Infectious Diseases (NIAID) |
2007-02 | PHASE2 |
| NCT01258322 | COMPLETED | Peritoneal Dialysis; Pioglitazone; Hypertriglyceridemia; Insulin Resistance; Inflammation |
Huashan Hospital |
2008-01 | |
| NCT01797666 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT01798940 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00727857 | COMPLETED | Diabetes Mellitus |
Takeda |
2007-06 | PHASE3 |
| NCT00494559 | COMPLETED | Diabetes Mellitus; Coronary Artery Stenosis |
Korea University Anam Hospital |
2007-07 | PHASE4 |
| NCT01432405 | COMPLETED | Type 2 Diabetes Mellitus |
Baylor College of Medicine |
2007-06 | PHASE4 |
| NCT00397631 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-12-19 | PHASE3 |
| NCT00099021 | COMPLETED | Head and Neck Cancer; Oral Leukoplakia |
National Cancer Institute (NCI) |
2003-06 | PHASE2 |
| NCT00575874 | COMPLETED | Type 2 Diabetes |
Daiichi Sankyo Co., Ltd. |
2007-08 | PHASE2 |
| NCT00203996 | TERMINATED | Polycystic Ovary Syndrome; Obstructive Sleep Apnea |
University of Chicago |
2003-09 | PHASE4 |
| NCT00926341 | COMPLETED | Metabolic Syndrome |
Aligarh Muslim University |
2006-10 | PHASE4 |
| NCT00571519 | TERMINATED | Type 2 Diabetes Mellitus |
Daiichi Sankyo |
2007-11-14 | PHASE3 |
| NCT00770497 | COMPLETED | Inflammation; Hypertension |
Takeda |
2007-03 | PHASE2 |
| NCT00411892 | TERMINATED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2006-11-29 | PHASE3 |
| NCT00328627 | COMPLETED | Type 2 Diabetes Mellitus |
Takeda |
2006-05 | PHASE3 |
| NCT00500331 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2007-01-23 | PHASE2 |
| NCT00372060 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-08-21 | PHASE3 |
| NCT00395512 | COMPLETED | Diabetes Mellitus |
Takeda |
2006-11 | PHASE3 |
| NCT00772174 | COMPLETED | Diabetes Mellitus |
Takeda |
2007-01 | PHASE3 |
| NCT00099853 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis Pharmaceuticals |
2004-05 | PHASE3 |
| NCT00402012 | COMPLETED | Diabetes Mellitus, Type 2 |
Pennington Biomedical Research Center |
2006-11 | PHASE4 |
| NCT00189163 | COMPLETED | Chronic Hepatitis C |
University of Michigan |
2005-01 | PHASE4 |
| NCT00433069 | COMPLETED | Chronic Hepatitis C |
University Hospital, Geneva |
2007-01 | PHASE2 |
| NCT00327015 | COMPLETED | Diabetes |
AstraZeneca |
2006-05 | PHASE3 |
| NCT00598013 | COMPLETED | Kidney Transplantation; Insulin Resistance; Atherosclerosis |
Yonsei University |
2004-11 | |
| NCT01090752 | COMPLETED | Diabetes; Hypertension |
University Hospital, Geneva |
2005-10 | PHASE4 |
| NCT00295633 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2006-03 | PHASE3 |
| NCT00225277 | COMPLETED | Diabetes Mellitus |
Takeda |
2003-07 | PHASE3 |
| NCT00368017 | TERMINATED | Chronic Kidney Disease |
Vanderbilt University |
2006-04 | PHASE2 |
| NCT00402909 | COMPLETED | Type 2 Diabetes |
Novartis Pharmaceuticals |
2006-11 | PHASE4 |
| NCT00286494 | COMPLETED | Diabetes Mellitus |
Takeda |
2006-02 | PHASE3 |
| NCT00571506 | COMPLETED | Diabetes Mellitus, Type 2; Vascular Diseases |
University of Arkansas |
2004-05 | PHASE4 |
| NCT00543959 | TERMINATED | Diabetes Mellitus Type 2 |
Merck Sharp & Dohme LLC |
2006-06 | PHASE2 |
| NCT00720577 | COMPLETED | Peripheral Arterial Disease |
Medtronic Endovascular |
2005-12 | EARLY_PHASE1 |
| NCT00297063 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2006-01-11 | PHASE3 |
| NCT00376181 | TERMINATED | Type 2 Diabetes |
Takeda |
2006-06 | PHASE3 |
| NCT01124656 | TERMINATED | Diabetes Mellitus, Type 2 |
Takeda |
2006-09 | PHASE3 |
| NCT00315146 | COMPLETED | Obesity; Overweight With Indications for Weight Loss |
Wake Forest University Health Sciences |
2006-04 | PHASE4 |
| NCT00108615 | COMPLETED | Glucose Metabolism Disorders; Diabetes |
US Department of Veterans Affairs |
2004-01 | PHASE4 |
| NCT02183337 | COMPLETED | Healthy |
Boehringer Ingelheim |
2007-02 | PHASE1 |
| NCT00196989 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2005-09 | PHASE2 |
| NCT00737347 | COMPLETED | Type 2 Diabetes; Obesity |
Northwestern University |
2003-09 | PHASE3 |
| NCT00328393 | COMPLETED | Hypertension; Diabetes Mellitus Type 2 |
University of Erlangen-Nürnberg Medical School |
2007-03 | PHASE3 |
| NCT00237237 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis |
2005-10 | PHASE3 |
| NCT00145340 | COMPLETED | Polycystic Ovary Syndrome |
Odense University Hospital |
2002-09 | PHASE4 |
| NCT00609856 | COMPLETED | Type 2 Diabetes; Secondary Drug Failure |
Skane University Hospital |
2004-04 | PHASE4 |
| NCT00226330 | TERMINATED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2005-03 | PHASE3 |
| NCT00322868 | COMPLETED | Cystic Fibrosis |
University Hospitals Cleveland Medical Center |
2006-04 | |
| NCT00819325 | COMPLETED | Coronary Artery Disease; Angina Pectoris; Type 2 Diabetes Mellitus; Percutaneous Coronary Intervention |
Queen Elizabeth II Health Sciences Centre |
2002-08 | PHASE4 |
| NCT00770575 | COMPLETED | Cardiovascular Diseases |
Takeda |
2005-06 | PHASE2 |
| NCT00754403 | COMPLETED | Diabetes Mellitus |
Takeda |
2005-07 | PHASE4 |
| NCT00214565 | TERMINATED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2004-08 | PHASE3 |
| NCT01396564 | COMPLETED | Type 2 Diabetes |
Coordinación de Investigación en Salud, Mexico |
2005-10 | PHASE1; PHASE2 |
| NCT00121667 | COMPLETED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2005-08 | PHASE3 |
| NCT00106808 | COMPLETED | Type 2 Diabetes Mellitus |
Bristol-Myers Squibb |
2005-08 | PHASE3 |
| NCT00816218 | COMPLETED | Type 2 Diabetes Mellitus |
The University of Texas Health Science Center at San Antonio |
2003-03 | PHASE4 |
| NCT00138554 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis |
2004-11 | PHASE3 |
| NCT00106704 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2005-03 | PHASE3 |
| NCT00229684 | TERMINATED | Diabetes Mellitus, Type 2 |
AstraZeneca |
2004-09 | PHASE2 |
| NCT00225264 | COMPLETED | Diabetes Mellitus |
Takeda |
2003-10 | PHASE3 |
| NCT00101803 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis Pharmaceuticals |
2005-01 | PHASE3 |
| NCT00143520 | COMPLETED | Type 2 Diabetes |
Daiichi Sankyo |
2004-12 | PHASE2; PHASE3 |
| NCT00364988 | COMPLETED | Type 2 Diabetes; Diabetic Nephropathy |
Shanghai Jiao Tong University School of Medicine |
2005-01 | |
| NCT00227110 | COMPLETED | Nonalcoholic Steatohepatitis |
The University of Texas Health Science Center at San Antonio |
2002-10 | PHASE4 |
| NCT00086502 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2004-06 | PHASE3 |
| NCT00308373 | COMPLETED | Diabetes Mellitus, Type 2 |
Mayo Clinic |
2004-07 | |
| NCT00762736 | COMPLETED | Diabetes Mellitus |
Takeda |
2004-07 | PHASE2 |
| NCT00094757 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2004-10-06 | PHASE3 |
| NCT00097279 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2004-08 | PHASE3 |
| NCT00086515 | COMPLETED | Diabetes Mellitus, Type II |
Merck Sharp & Dohme LLC |
2004-06-30 | PHASE3 |
| NCT00494312 | COMPLETED | Diabetes Mellitus; Liver |
Takeda |
2000-10 | PHASE4 |
| NCT00240370 | COMPLETED | Type 2 Diabetes |
Bristol-Myers Squibb |
2003-10 | PHASE3 |
| NCT00982202 | COMPLETED | Alzheimer Disease |
National Institute on Aging (NIA) |
2002-01 | PHASE2 |
| NCT00672919 | COMPLETED | Diabetes Mellitus |
Takeda |
2003-11 | PHASE4 |
| NCT00676260 | COMPLETED | Diabetes Mellitus |
Takeda |
2002-12 | PHASE2 |
| NCT01799850 | COMPLETED | Diabetes Type 2 |
East Tennessee State University |
2002-03 | PHASE4 |
| NCT00598793 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2002-11 | PHASE3 |
| NCT00331487 | COMPLETED | Diabetes Mellitus |
Takeda |
2000-09 | PHASE3 |
| NCT00521820 | TERMINATED | Diabetes Mellitus |
Takeda |
2000-06 | PHASE3 |
| NCT00649558 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2003-02 | PHASE1 |
| NCT00649012 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2003-03 | PHASE1 |
| NCT00521742 | COMPLETED | Diabetes Mellitus |
Takeda |
2001-03 | PHASE3 |
| NCT00232362 | WITHDRAWN | Type 2 Diabetes Mellitus |
Texas Tech University Health Sciences Center |
2007-06 | PHASE1 |
| NCT00269061 | COMPLETED | Non-Insulin-Dependent Diabetes Mellitus |
GlaxoSmithKline |
2006-01 | PHASE1 |
| NCT00013598 | COMPLETED | Fatty Liver; Nonalcoholic Steatohepatitis |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2001-03 | PHASE2 |
| NCT00159211 | TERMINATED | Type 2 Diabetes |
Assistance Publique - Hôpitaux de Paris |
2005-05 | |
| NCT00154037 | COMPLETED | Healthy Subjects |
Technische Universität Dresden |
2005-10 | |
| NCT00212290 | COMPLETED | Insulin Resistance; Type 2 Diabetes Mellitus |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2002-11 | PHASE4 |
| NCT00148850 | TERMINATED | HIV-Associated Lipodystrophy Syndrome; HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2003-02 | PHASE3 |
| NCT00290940 | COMPLETED | Diabetes Mellitus, Type 2 |
Daiichi Sankyo |
2006-01 | PHASE2 |
| NCT00377975 | COMPLETED | Obesity |
Pennington Biomedical Research Center |
2003-01 | PHASE2 |
| NCT00015626 | COMPLETED | Insulin Resistance; Diabetes Mellitus |
National Center for Research Resources (NCRR) |
PHASE2 | |
| NCT01161394 | COMPLETED | Inflammation |
University at Buffalo |
PHASE4 | |
| NCT00306826 | WITHDRAWN | Glucose Metabolism Disorders |
University of Leipzig |
PHASE4 | |
| NCT00189774 | COMPLETED | Type 2 Diabetes Mellitus; Diabetes Mellitus, Type II |
Astellas Pharma Inc |
PHASE2; PHASE3 | |
| NCT00459940 | COMPLETED | Growth Hormone Deficiency |
University of Aarhus |
2004-09 | |
| NCT00482183 | COMPLETED | Coronary Artery Disease; Type 2 Diabetes Mellitus |
Showa University |
2003-07 | PHASE2; PHASE3 |
| NCT00576784 | COMPLETED | Type 2 Diabetes Mellitus; Insulin Resistance |
IKFE Institute for Clinical Research and Development |
2005-04 | PHASE4 |
| NCT00242177 | COMPLETED | Multiple Sclerosis, Relapsing-Remitting |
University of Illinois at Chicago |
2003-10 | PHASE1 |
| NCT00276497 | COMPLETED | Diabetes |
M.V. Hospital for Diabetes |
2003-10 | PHASE1 |
| NCT00151710 | COMPLETED | Congenital Adrenal Hyperplasia |
Radboud University Medical Center |
||
| NCT00384215 | COMPLETED | Diabetes Mellitus, Type 2 |
Sanofi |
2001-12 | PHASE4 |
| NCT00314561 | COMPLETED | Metabolic Syndrome |
Korea University Anam Hospital |
2006-05 | PHASE4 |
| NCT00352287 | COMPLETED | Obesity; Metabolic Syndrome; Impaired Glucose Tolerance |
Stanford University |
2003-03 | PHASE4 |
| NCT00479986 | COMPLETED | Type 2 Diabetes Mellitus; Cardiovascular Disease |
IKFE Institute for Clinical Research and Development |
2005-06 | PHASE4 |
| NCT00155350 | UNKNOWN | Coronary Atherosclerosis; Inflammation; Coronary Heart Disease |
National Taiwan University Hospital |
2004-11 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2025-08-27)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Pioglitazone (U-72107) Solubility in DMSO
- Pioglitazone (U-72107) Stock Solution
- Pioglitazone (U-72107) Storage
- Pioglitazone (U-72107) Stability
- Pioglitazone (U-72107) Molecular Weight
- Pioglitazone (U-72107) SMILES
- Pioglitazone (U-72107) CAS Number
- Pioglitazone (U-72107) Chemical Structure (2D and 3D)
- Pioglitazone (U-72107) SDS|MSDS